Estimated Time
1.0
Release Date
Jul 11,2022
Expiration Date
Jul 10, 2023
The data are in! Unimolecular multiagonists have demonstrated efficacy by concurrent activation of hormone receptors that affect energy homeostasis. Learn how emerging agents offer robust glucose control, with a low risk of hypoglycemia, as well as weight loss. This activity is a compilation of the highlights of satellite symposia originally presented live at ADA’s 82nd Scientific Sessions and ENDO 2022
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows, nurse practitioners, and physician assistants engaged in the care of patients with T2D.
After completing this CE activity, the participant should be better able to:
- Plan strategies to address unmet needs, including treatment initiation and escalation, for diverse patient populations with T2D
- Assess the clinical implications of emerging evidence regarding the incretin effect and the roles of GLP-1 and GIP
- Relate the pathophysiology of GLP-1 and GIP to potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
- Evaluate and interpret the implications of efficacy and safety data of novel dual agonists for T2D
- Addressing unmet needs in T2D
- Delineating the incretin effect and the roles of GLP-1 and GIP
- Potential benefits of agonism of multiple receptors that affect energy homeostasis
- Clinical implications of tirzepatide efficacy and safety data
- Recap of key points
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Medical Learning Institute, Inc. (MLI). The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 CreditsTM
The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this activity is not intended to provide extensive training or certification in the field.
The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this activity is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1 Credit™, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Statement of Independence
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until July 10, 2023. PAs should only claim credit commensurate with the extent of their participation.
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until July 10, 2023. PAs should only claim credit commensurate with the extent of their participation.Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.Medical Learning Institute, Inc., and Endocrine Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
Juan Pablo FriasMedical Director and Principal Investigator
Velocity Clinical Research
Los Angeles, CA
Dr. Frias is Medical Director and Principal Investigator of the National Research Institute in Los Angeles, CA. He received his medical degree from Vanderbilt University School of Medicine and completed his Fellowship in Endocrinology, Diabetes, and Metabolism at the University of California, San Diego.
Dr. Frias has held academic positions at the University of Colorado Health Sciences Center, Barbara Davis Center for Diabetes, and the University of California San Diego School of Medicine. He has been involved in diabetes and metabolism-related research for more than 25 years and has authored numerous publications in this field.
David A. D’AlessioProfessor of Medicine
Chief, Division of Endocrinology and Metabolis m
Duke University School of Medicine
Durham, NC
Chief, Division of Endocrinology and Metabolis m
Duke University School of Medicine
Durham, NC
Dr. D’Alessio is a practicing endocrinologist and Director of Duke Endocrinology. His research group studies regulation of insulin secretion by hormonal factors and the abnormalities of islet function in type 2 diabetes. In particular, Dr. D’Alessio has focused on understanding the insulinotropic properties of the hormones glucagon and glucagon-like peptide 1, their role in diabetes and application to therapeutics. D’Alessio and his colleagues do translational work that connects mechanistic studies in animal models to studies of human physiology. Major contributions from this work includes identifying key brain areas that respond to GLP-1 and control insulin secretion, the role of islet products to control insulin secretion through local actions, and the role of GLP-1 on glucose regulation in patients with bariatric surgery. Beyond his clinical and research activities at Duke, Dr. D’Alessio has been a member of several NIH study sections including a role as chair, a consultant to the NIDDK council, and currently serves as Editor-in-Chief for the journal Diabetes.
Ildiko LingvayProfessor of Medicine
Department of Internal Medicine/ Endocrinology
Department of Population and Data Sciences
Medical Director, Office of Clinical Trials Management
UT Southwestern Medical Center
Dallas, TX
Dr. Lingvay is Professor of Medicine in the Division of Endocrinology as well as the Department of Population and Data Sciences at UT Southwestern Medical Center. Dr. Lingvay is the Medical Director of the Office of Clinical Trials Management, overseeing all clinical trials at UT Southwestern. She is Board Certified both in Obesity Medicine as well as Endocrinology, Diabetes and Metabolism.
Dr. Lingvay leads a program that focuses on clinical research in the field of obesity and type 2 diabetes, with the ultimate goal to improve the lives of all patients who suffer so many health consequences as a result of their medical problems. Her research interests span the spectrum from pathophysiology of the disease to treatment algorithms and comparative effectiveness of various therapeutic approaches. Dr. Lingvay treats patients at the UT clinics and hospitals as well as the Parkland Health & Hospital System.
Dr. Lingvay is an active member of the American Diabetes Association, where she has served over the years on several committees, including the Organizing Committee for the Annual Scientific Sessions, Focus on Fellows Advisory Board, and WIN-ADA Advisory Board. She has participated in many clinical trials and has a special interest in cardiovascular outcome trials. She authored over 110 publications in major medical journals and authored chapters in several popular diabetes textbooks.
Donna RyanProfessor Emerita
Pennington Biomedical Research Center
Baton Rouge, LA
Pennington Biomedical Research Center
Baton Rouge, LA
Dr. Ryan is Professor Emerita at Pennington Biomedical in Baton Rouge, LA, USA, where she oversaw Clinical Research for 25 years. Her research interests included lifestyle intervention and diet for weight loss, and she was an investigator on NIH studies including POUNDS Lost, Look AHEAD, DPP, and DASH. These studies generated data to influence guidelines and policies for weight management. She was Principal Investigator for a series of studies for the US Department of Defence which targeted military nutrition approaches to improve soldier readiness and performance. A particular research interest was improving primary care management of obesity and evaluating commercial approaches to weight management. She also studies the use of medications and devices to aid weight management. She was President of The Obesity Society and was designated Master of Obesity Medicine by the American Board of Obesity Medicine. She received The Obesity Society’s George Bray Founder’s Award (2013) and the George Blackburn Award (2019), was named Obesity Action Coalition Health Care Provider of the Year (2017), and was invited to give the Francisco Balmis Lecture (2019).
Currently, Dr. Ryan serves as Past President of the World Obesity Federation, Co-Chair of the SELECT Steering Committee and member of the Data Safety Monitoring Board for setmelanotide. She has more than 300 publications and remains an active consultant and advisor to companies developing drugs, devices, lifestyle programs and medical approaches to obesity management.
Michael A. NauckProfessor and Head of Clinical Research
Diabetes Division, St. Josef Hospital
Ruhr University
Bochum, Germany
Diabetes Division, St. Josef Hospital
Ruhr University
Bochum, Germany
Professor Nauck has a particular research interest in the role of gastrointestinal peptide hormones (incretins: glucose dependent insulinotropic polypeptide, GIP, and glucagon like peptide 1, GLP 1) in the physiological regulation of metabolism and in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a therapeutic potential of GLP 1 in type 2 diabetes. He has contributed to the development of incretin based glucose lowering medications such as GLP 1 receptor agonists and inhibitors of dipeptidyl peptidase 4. Additional areas of interest include spontaneous hypoglycaemia (insulinomas), pancreas transplantation, cardiovascular complications of type 2 diabetes, and the modification of cardiovascular risk in type 2 diabetic patients with glucose lowering pharmacotherapy. His scientific contributions have been honoured with several awards, including the Ferdinand
Bertram Award (1993), the Werner Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the German Diabetes Association.
Bertram Award (1993), the Werner Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the German Diabetes Association.
He has served as reviewer for all major diabetes journals and has published more than 240 original articles and 130 reviews and book chapters. His publications have been quoted > 55000 times, his “H index” is 102, and he has been a “highly cited researcher” (among the top 1 %) in 2019 (Web of Science). Professor Nauck is member of a number of professional societies, including the German, European, American Diabetes Associations, and the International Diabetes Federation.
Planner/Presenter
Juan Pablo Frias, MD, Velocity Clinical Research, Los Angeles, CA
Juan Pablo Frias, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi; Research Grant from Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi; Speakers’ Bureau with Lilly, Merck, and Sanofi.
Juan Pablo Frias, MD, Velocity Clinical Research, Los Angeles, CA
Juan Pablo Frias, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi; Research Grant from Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi; Speakers’ Bureau with Lilly, Merck, and Sanofi.
Planner/Presenter
David A. D’Alessio, MD, Duke University School of Medicine, Durham, NC
David A. D’Alessio, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Lilly and Sun Pharma; Research Grant from Lilly and Merck.
David A. D’Alessio, MD, Duke University School of Medicine, Durham, NC
David A. D’Alessio, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Lilly and Sun Pharma; Research Grant from Lilly and Merck.
Planner/Presenter
Ildiko Lingvay, MD, MPH, MSCS, UT Southwestern Medical Center, Dallas, TX
Ildiko Lingvay, MD, MPH, MSCS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for AstraZeneca, Bayer, Intarcia, Intercept, Lilly, and Merck;
The following relationships have ended within the last 24 months: Advisory Board/Consultant for Boehringer Ingelheim, Novo Nordisk, and Sanofi; Research Grant from Boehringer Ingelheim, Merck/Pfizer, Mylan, Novo Nordisk, and Sanofi.
Ildiko Lingvay, MD, MPH, MSCS, UT Southwestern Medical Center, Dallas, TX
Ildiko Lingvay, MD, MPH, MSCS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for AstraZeneca, Bayer, Intarcia, Intercept, Lilly, and Merck;
The following relationships have ended within the last 24 months: Advisory Board/Consultant for Boehringer Ingelheim, Novo Nordisk, and Sanofi; Research Grant from Boehringer Ingelheim, Merck/Pfizer, Mylan, Novo Nordisk, and Sanofi.
Planner/Presenter
Donna Ryan, MD, Pennington Biomedical Research Center, Baton Rouge, LA
Donna Ryan, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Altimmune, Amgen, Calibrate, Epitomee, Gila, Lilly, Novo Nordisk, Roman, Scientific Intake, Wondr Health, Xeno Bioscience, YSOPIA, and Zealand; Speakers’ Bureau with Novo Nordisk; Other: Stock Options with Calibrate, Epitomee, Roman, and Scientific Intake. On Data Safety Monitoring Board for Rhythm. Co-chair of steering committee for the SELECT Trial for Novo Nordisk.
Donna Ryan, MD, Pennington Biomedical Research Center, Baton Rouge, LA
Donna Ryan, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Altimmune, Amgen, Calibrate, Epitomee, Gila, Lilly, Novo Nordisk, Roman, Scientific Intake, Wondr Health, Xeno Bioscience, YSOPIA, and Zealand; Speakers’ Bureau with Novo Nordisk; Other: Stock Options with Calibrate, Epitomee, Roman, and Scientific Intake. On Data Safety Monitoring Board for Rhythm. Co-chair of steering committee for the SELECT Trial for Novo Nordisk.
Planner/Presenter
Michael A. Nauck, MD, St. Josef Hospital, Ruhr University, Bochum, Germany
Michael A. Nauck, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Boehringer Ingelheim, Gasherbrum, Inventiva, Lilly, Merck Sharp & Dohme Corp., Novo Nordisk, Pfizer, Sanofi, and Servier;
The following relationships have ended within the last 24 months: Advisory Board/Consultant for AstraZeneca, Berlin-Chemie, and Regor Therapeutics.
Michael A. Nauck, MD, St. Josef Hospital, Ruhr University, Bochum, Germany
Michael A. Nauck, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Boehringer Ingelheim, Gasherbrum, Inventiva, Lilly, Merck Sharp & Dohme Corp., Novo Nordisk, Pfizer, Sanofi, and Servier;
The following relationships have ended within the last 24 months: Advisory Board/Consultant for AstraZeneca, Berlin-Chemie, and Regor Therapeutics.
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and the Endocrine Society, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
All of the relevant financial relationships of individuals for this activity have been mitigated.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Once submitted, the certificate will be automatically generated as a PDF online.
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Once submitted, the certificate will be automatically generated as a PDF online.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Marissa Grossman via email at mgrossman@mlieducation.org
Support Statement
This activity is supported by an educational grant from Lilly.
About this Activity
The Endocrine Society and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and the Endocrine Society.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc., Endocrine Society, or any of its partners, providers, and/or supporters.
